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Abstract
Background: Current cigarette smoking is associated with reduced acute responses to corticosteroids and worse clinical
outcomes in stable chronic asthma. The mechanism by which current smoking promotes this altered behavior is currently
unclear. Whilst cytokines can induce corticosteroid insensitivity in-vitro, how current and former smoking affects airway
cytokine concentrations and their responses to oral corticosteroids in stable chronic asthma is unclear.
Objectives: To examine blood and sputum cytokine concentrations in never, ex and current smokers with asthma before
and after oral corticosteroids.
Methods: Exploratory study utilizing two weeks of oral dexamethasone (equivalent to 40 mg/day prednisolone) in 22
current, 21 never and 10 ex-smokers with asthma. Induced sputum supernatant and plasma was obtained before and after
oral dexamethasone. 25 cytokines were measured by multiplex microbead system (Invitrogen, UK) on a Luminex platform.
Results: Smokers with asthma had elevated sputum cytokine interleukin (IL) -6, -7, and -12 concentrations compared to
never smokers with asthma. Few sputum cytokine concentrations changed in response to dexamethasone IL-17 and IFNa
increased in smokers, CCL4 increased in never smokers and CCL5 and CXCL10 reduced in ex-smokers with asthma. Ex-
smokers with asthma appeared to have evidence of an ongoing corticosteroid resistant elevation of cytokines despite
smoking cessation. Several plasma cytokines were lower in smokers with asthma compared to never smokers with asthma.
Conclusion: Cigarette smoking in asthma is associated with a corticosteroid insensitive increase in multiple airway
cytokines. Distinct airway cytokine profiles are present in current smokers and never smokers with asthma and could
provide an explanatory mechanism for the altered clinical behavior observed in smokers with asthma.
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Introduction
Cigarette smoking reduces acute treatment responses to
corticosteroids [1,2,3,4,5,6,7,8,9], and is associated with increased
symptoms [10,11] and unscheduled emergency department visits
in patients with asthma [12]. A long lasting effect of former
smoking on the therapeutic effects of corticosteroids in asthma is
also suggested by the attenuated responses found in ex-smokers
with asthma with significant smoking histories [8,9]. As a history of
current or past smoking is present in approximately half of subjects
with asthma, cigarette smoking could be viewed as one of the most
important environmental factors influencing this condition.
Whilst the impact of smoking on airway inflammation in asthma
has become clearer over recent years, the mechanism/s by which
cigarette smoking reduces corticosteroid responses in asthma is still
unknown. Alteration of airway cytokine profiles in response to
current and former cigarette smoking is a plausible candidate
mechanism as previous research has demonstrated that combina-
tions of cytokines can alter corticosteroid responsiveness in-vitro
[13,14,15,16]. Increased concentrations of sputum supernatant
interleukin (IL)-8 (CXCL8) [17], endobronchial interferon (IFN)-c
[18] and reduced sputum supernatant IL-18 [19] have been
observed in smokers with asthma, leading us to hypothesize that
cigarette smoking induced alterations in the airway cytokine
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71460
environment in asthma could be contributing to the reduced acute
airway responses to corticosteroids observed in this group.
Therefore we measured a broad selection of cytokines in sputum
supernatant and plasma in a group of subjects with asthma with
differing smoking histories, both before and after an oral
corticosteroid trial to gain insights into the effect of current and
former smoking on cytokine profiles and their responses to
corticosteroids in asthma.
Our results suggest that cigarette smoking promotes a cortico-
steroid insensitive alteration in airway inflammation in asthma
which may be responsible for the altered clinical phenotype in
current smokers with asthma and that long term cessation of
smoking does not restore airway cytokine expression to the pattern
observed in never smokers with asthma. Given the frequency of
current and former cigarette smoking in asthma our findings
potentially have implications for both current approaches to
treatment and the development and licensing of new treatments
for adults with stable asthma. Further research in this area is
required to examine and extend the findings presented herein.
Methods
Subjects and Study Design
Three groups of patients, (i) current smokers, (ii) ex-smokers and
(iii) never smokers with stable asthma were recruited from hospital
out-patient clinics, general practices and previous studies to an
exploratory study with open label, unblinded use of oral
dexamethasone. Our exclusion criteria were: requirement for
treatment with or the presence of conditions likely to be
exacerbated by oral corticosteroids, intention to stop smoking or
become pregnant, current pregnancy or any additional major
chronic illness. Treatment with up to a maximum of 2000 mg
beclometasone (or equivalent) per day, long acting beta2 agonists
and leukotriene receptor antagonists was allowed. In an attempt to
guide study design we performed a power calculation based on
previously published results [8]. Using this information we
estimated that if twenty subjects were recruited to both the
smokers and never smokers with asthma groups would could
expect to have 80% power to detect a between group difference of
at least 336.4 ml in pre-bronchodilator FEV1 in response to the
oral dexamethasone trial.
Ethics Statement
All subjects provided written informed consent prior to
participation and the study was reviewed and approved by the
West of Scotland ethics committee.
We defined stable asthma as no emergency clinic or hospital
visit, oral corticosteroid prescription or change in asthma
treatment in the preceding month. Current smoking was
defined as $5 cigarettes/day and $5 pack year history. Ex-
smokers with asthma were eligible if they had ceased smoking
two or more years from the date of recruitment, were former
daily smokers of $5 cigarettes and had a $5 pack year history.
‘Never smoking’ subjects were required to have no history of
regular daily smoking and to be current non-smokers. All
subjects performed urine cotinine (SmokeScreenTM sampling
system, GFC Diagnostics, UK) and exhaled carbon monoxide
testing (Pico SmokerlyserH, Bedfont Scientific Ltd, UK) at each
visit to confirm smoking status. Smokers were required to
abstain from smoking for at least three hours prior to tests
whilst inhaled bronchodilator was withheld as per international
guidelines for testing. Inhaled corticosteroids were withheld for
twenty four hours prior to testing.
Eligibility for the study required demonstration of reversible
airflow obstruction [FEV1 bronchodilator response to b2 agonist of
$12% and .200 ml], peak expiratory flow (PEF) lability or a
positive methacholine challenge test. All lung function assessments
met international consensus guidelines [20,21,22]. Current and
ex-smokers with asthma were required to have an FEV1.80%
predicted before entry by methacholine challenge testing (to
reduce confounding with chronic obstructive pulmonary disease).
Airway corticosteroid sensitivity was assessed by change in pre-
bronchodilator FEV1 to a two week trial of oral dexamethasone
(6 mg/1.74 m2; roughly equivalent to 40 mg prednisolone/day).
On the day prior to and on completion of the dexamethasone
course all subjects performed spirometry, exhaled nitric oxide
measurement at 50 ml/sec (Niox Flex, Aerocrine AB, Sweden),
induced sputum and completed asthma control questionnaires
(ACQ) [23]. Plasma was obtained by venepuncture to allow
measurement of cytokines before and after the corticosteroid trial.
Serum cortisol was assessed on completion of the dexamethasone
course, subjects were deemed to have been compliant if their
blood cortisol level was below 50 nmol/l.
Sputum and Plasma Cytokine Measurement
Sputum samples were processed using the whole sputum sample
method [24]. Briefly, homogenization was achieved using gentle
mechanical disruption in low concentrations of dithiothreitol
(0.05%). Samples with oral epithelial counts .80% were
discarded. Sputum supernatants were collected and stored in
aliquots at -80uC until processing. Plasma was collected from
heparinised blood samples. Sputum supernatant and plasma was
examined for mediators informative of pro and anti-inflammatory
functions and Th1, Th2 and Th17 responses relevant to asthma
using a multiplex immuno-detection system (25-plex cytokine
assay, Invitrogen Ltd, UK) and a Luminex 100TM analyzer
(Luminex Corporation, USA). The cytokines detected [assay kit
detection limit in pg/ml] were interleukin (IL)-1 receptor
antagonist (IL1RA) [10], IL-1b [18], IL-2 [6], IL-2 receptor
(IL2R) [24], IL-4 [5], IL-5 [3], IL-6 [3], IL-7 [10], IL-10 [5], IL-
12 (p40/p70) [5], IL-13 [10], IL-15 [10], IL-17 [16], interferon
(IFN)a [10], IFNc [5], granulocyte macrophage colony-stimulat-
ing factor (GM-CSF) [5], tumor necrosis factor (TNF)-a [5], C-X-
C motif chemokine ligand (CXCL)8 [3], CXCL9 [6], CXCL10
[5], CC motif chemokine ligands (CCL)2 [10], CCL3 [10], CCL4
[10], CCL5 [15] and CCL11 [5]. Values that could not be
confidently calculated were assigned a value half-way between the
manufacturers lowest recommended detection level and zero to
allow for statistical examination via logarithmic transformation.
Plasma cytokines were not assessed in ex-smokers with asthma.
Statistical Analysis
Between group comparisons were performed for smokers and
never smokers with asthma only. Normal and non-normal
distributed variables were analyzed using t-tests and Mann-
Whitney U test respectively. For within group before/after
dexamethasone treatment comparisons, paired t-test and Wil-
coxon signed rank test were applied. Subjects’ post-corticosteroid
data were utilized if there was evidence of compliance (as assessed
by serum cortisol levels). Correlations were performed using
Pearson’s correlation. Adjustment for multiple comparisons was
not performed as all analyses were treated as exploratory.
Principal component analysis was performed using the corre-
lation matrix from the pre dexamethasone sputum dataset. The
decision on number of principal components present was guided
by inspection of the scree plot requirement for eigenvalues of
greater than 1. Principal component loadings were employed to
Smoking Alters Asthma Airway Cytokine Profiles
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e71460
derive a qualitative description of the sputum cytokine profiles
with reference to patient group (figures 1 and S1). Interpretation of
principal components was guided by inspection of the derived
loadings leading to a description based on the dominant
contributing variables. Analysis was performed on SAS v 9.1
(TS1M3) for Windows (SAS Institute Inc., NC, USA) and
MINITAB 15 (Minitab Inc. State College, PA, USA).
Results
Fifty three patients with asthma (22 current smokers, 21 never
smokers and 10 ex-smokers) agreed to participate in the study and
twenty smokers, nine ex-smokers and seventeen never smokers
with asthma were compliant with the oral corticosteroid trial
(confirmed by serum cortisol). Of these, eighteen current smokers,
nine ex-smokers and sixteen never smokers with asthma provided
a satisfactory sputum sample at both visits.
Baseline Demographics
The groups were generally well balanced (Table 1). However
the smoker and ex-smoker groups were prescribed higher daily
inhaled corticosteroid doses and had higher ACQ scores. The
bronchodilator response of the smoker group was lower compared
to never-smokers with asthma. Smokers with asthma had reduced
exhaled nitric oxide levels compared to both ex-smokers and never
smokers with asthma. Sputum cellular profiles were equivalent
across the three groups with no neutrophilia or eosinophilia
evident.
Lung Function Response to Dexamethasone
The never-smokers with asthma group made a significant
within-group improvement in lung function in response to oral
dexamethasone (FEV1 change; 173 ml (95% CI: 10, 336),
p = 0.039), in contrast to current smokers with asthma (smokers;
32 ml (2115, 178), p = 0.657). The response of ex-smokers with
asthma was variable and overlapped that observed in the never-
smokers with asthma (ex-smokers; 257 ml (2154, 667), p = 0.188).
No statistically significant relationship was evident between lung
function response to oral dexamethasone and either time since
cessation of smoking or total pack years in ex-smokers with asthma
(data not shown).
Sputum Cell Change in Response to Dexamethasone
The proportion of eosinophils in samples from smokers with
asthma changed in response to oral dexamethasone and was
equivalent to that observed in non-smokers with asthma (smokers
change 20.4% (95% CI 20.8, 0.0), non-smokers 20.2% (22.0,
0.0), p = 0.430). Smokers with asthma also demonstrated a trend to
a reduction in sputum neutrophil percentage (change 212.0%
(225.01, 1.99), p = 0.081). However no difference was evident
when compared to the neutrophil change observed in non-smokers
(Table 2).
Sputum Supernatant Cytokines
Expression levels were below the manufacturers recommended
minimum detection level in the majority of subjects for a number
of cytokines (IL2, 4, 10, 15, TNFa, CCL11 and IFNc (see table S1
for detailed description)). Therefore significance tests for these
cytokines will not be presented and results for these cytokines were
not employed in multivariate analysis. However the remainder of
the cytokines and chemokines tested were detectable in the
majority of subjects. The summary data for all sputum supernatant
cytokines tested (including those with median levels below the
manufacturers recommended minimum level) are presented in
Table 3.
Given the difference in baseline inhaled corticosteroid doses,
analysis incorporating adjustment of sputum cytokine results for
regular inhaled corticosteroid dose was performed to assess the
potential impact. Adjustment for baseline inhaled corticosteroid
dosage did not reduce any of the differences evident and
strengthened some (e.g. IL12, IL17). Based on this finding we
present the unadjusted results.
Figure 1. Principal component analysis plot of pre dexamethasone sputum supernatant cytokines (IL1b, 1RA, 2R, 6, 7, 13, 17, IFNa,
GM-CSF, CCL2, 3, 4 & 5, CXCL8, 9 & 10). Principal component 1 represents 52% of variance in data, Principal component 2 21%. Based on
examination of the component loadings (Table 3) we interpret principal component 1 as being principally driven by the sputum supernatant
cytokines IL1b, 2R, 7, 12, 13, 17 & GM-CSF principal component 2 to be driven by sputum supernatant IL-6 and the chemokines CXCL9 & 10 & CCL 2.
doi:10.1371/journal.pone.0071460.g001
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Pre Dexamethasone Sputum Supernatant Cytokines
Smokers with asthma demonstrated elevated concentrations of a
number of sputum supernatant cytokines compared to never
smokers with asthma (Table 3). Specifically, smokers with asthma
had raised IL-6 (p,0.001), IL-7 (p= 0.033) and IL-12 (p = 0.042).
IL1RA (p= 0.055), IL-17 (p= 0.072) and CCL2 (p= 0.083)
demonstrated a tendency to a significantly higher concentration
in smokers with asthma. Several sputum cytokines also appeared
to be raised in ex-smokers with asthma compared to never smokers
with asthma (see Table 3 and table S2).
Principal component analysis employing the majority of the pre
dexamethasone sputum supernatant cytokines was performed
using the data from smokers and never smokers with asthma alone.
This suggested a three component solution explaining more than
88% of the variance in the data (Table 4). The first two
components explained 73% of the variance (principal component
(PC) 1 52% and PC2 21%). Loadings to PC1 were generally low
with none above 0.4 whilst there were several variables loading at
greater than 0.4 to PC2. The majority of the variance for PC1 and
2 appeared to be driven by the current smokers with asthma
(Figure 1). Analysis including the data for ex-smokers was also
performed (see figure S1).
Sputum Supernatant Cytokines-dexamethasone
Response
Few statistically significant within-group changes were evident
in response to oral dexamethasone. Smokers with asthma
demonstrated an increase in sputum IFNa of 53.5 pg/ml (95%
CI 12.1, 94.8), p = 0.014, and in IL-17 of 235.3 pg/ml (83.4,







Age (years) 46.6 (6.7) 49.8 (9.0) 42.5 (10.0)
Gender (F:M) 12:10 5:5 11:10
BMI (kg/m2) 26.6 (6.0) 31.2 (5.3) 28.9 (5.1)
Asthma Duration (years) 22.1 (15.9) 24.6 (15.9) 28.6 (15.0)
Atopy (yes/no/unknown) 10/6/6 4/4/2 15/3/3
Pack years smoked Median (IQR) 26.5 (15, 35) 24 (20, 30)
Current cigarettes/day Median (IQR) 17.5 (15, 20)
Duration of smoking cessation (years) 7.7 (4.5)
Inhaled steroid (mcg/day; beclometasone equivalent)
Median (IQR)
800* (800, 1600) 1000 (800, 2000) 800 (750, 1000)
ACQ Score (0 to 6) 2.2* (0.9) 2.3 (0.7) 1.5 (0.8)
Pre BD FEV1 (% predicted) 73.6 (18.5) 79.7 (24.1) 73.3 (15.3)
Pre BD PEF (% predicted) 81.7 (20.8) 85.4 (24.7) 85.8 (19.1)
FEV1 BD response median (IQR) 16.4 (13.8, 23.3) 20.0 (13.0, 35.9) 28.5 (14.0, 37.5)
Pre dexamethasone FENO50 (ppb) median (IQR) 11.1* (3.6, 13.5) 19.8 (15.8, 43.5) 32.8 (17.7, 73.2)
Total cell count (106) median (IQR) 7.4 (3.4, 12.3) 10.3 (5.2, 15.3) 5.3 (3.8, 7.8)
Sputum eosinophils (% of total) median (IQR) 0.4 (0, 1) 1.0 (0.1, 5) 0.3 (0, 2)
Sputum neutrophils (% of total) median (IQR) 34 (24, 56) 37 (22, 63) 24 (10.5, 41)
Data presented as means with standard deviation (SD) except where indicated.
*p#0.05 relative to never smokers with asthma.
Abbreviations: ACQ; asthma control questionnaire, BD; bronchodilator, BMI; body mass index, mcg;
microgramme, FEV1; forced expiratory volume in 1 sec, IQR; interquartile range, PEF; peak expiratory flow.
doi:10.1371/journal.pone.0071460.t001
Table 2. Sputum profiles changes in response to dexamethasone.
Smokers with asthma Ex-Smokers with asthma Never-Smokers with asthma
(n=18) (n =9) (n=16)
D total viable cell count 10*6 cells 0.08 (0.36) 0.23 (0.77) 20.11 (0.54)
D eosinophil % 20.69 (2.87) 22.82 (3.63) 21.26* (2.48)
D neutrophil % 27.2 (21.3) 4.1 (28.1) 0.6 (32.7)
D macrophages % 21.3 (23.4) 25.7 (18.9) 27.4 (25.0)
D lymphocytes % 20.02 (0.67) 0.00 (0.05) 20.26 (0.64)
D bronchial epithelial cells % 9.5* (16.2) 4.3 (19.5) 8.0 (20.5)
Data presented as mean (SD). D; change. *p,0.05 (within group change).
doi:10.1371/journal.pone.0071460.t002
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387.2), p = 0.012. A similar but non-significant trend was also
evident for these cytokines in never smokers with asthma (IFNa;
24.7 pg/ml (24.0, 53.5), p = 0.087, IL-17; 66.4 pg/ml (28.7,
141.4), p = 0.079). An increase in CCL4 was evident in the never
smokers with asthma (31.6 pg/ml (4.6, 58.5), p = 0.03). Some
sputum cytokines also appeared to change in ex-smokers with
asthma response to dexamethasone (see text S1).
In an attempt to gain insights into the relationship between
corticosteroid resistance in airway responses and airway cytokines
we examined correlations between CCL4, IFNa and IL-17 and
change in FEV1% predicted and ACQ score. However no
significant correlations were evident (data not shown).
Plasma Cytokines
Several differences were evident when both groups were
compared (Table 5 (and Table S3 for description of samples
below manufacturers recommended minimum level). In general,
the current smoker group had lower plasma cytokines, with
significantly reduced median plasma concentrations of IL1RA
(p= 0.019), IL-12 (p = 0.046), IL-13 (p = 0.003) and GM-CSF
(p = 0.021).
Following the oral dexamethasone trial a number of plasma
cytokines were found to be significantly lower in smokers with
asthma (compared to never smokers with asthma) (Table 5). These
were IL1RA (p= 0.028), IL-7 (p = 0.005), IL-13 (p= 0.012), IFNa
(p = 0.028), CXCL10 (p = 0.007), CCL3 (p= 0.011) and CCL4
(p = 0.007).
Discussion
Our findings demonstrate a clear impact of current smoking on
sputum cytokine profiles in patients with stable chronic asthma.
An additional important finding is that the cytokine profiles in
both current and former smokers with asthma appear to be
insensitive to high dose oral corticosteroids. We believe the
presented results are of importance for several reasons. Cigarette
smoke is known to be a potent immunomodulator [25] and there is
ample evidence for an adverse impact of smoking on asthma. For
Table 3. Sputum supernatant cytokine concentrations before and after two weeks of oral dexamethasone.
Smokers with asthma Ex-smokers with asthma Never smokers with asthma
Pre-steroid (n=20) Post-steroid (n =18) Pre-steroid (n =10) Post-steroid (n =9) Pre-steroid (n =21) Post-steroid (n =16)
IL-1RA 12480 (3475, 18561) 161402 (4208, 23359) 5206 (3175, 8231) 12168 (6445, 17519) 3449 (1952, 8641) 4838 (2486, 8711)
IL-1b 19.4 (9.0, 34.4) 28.93 (9.0, 84.0) 13.5 (9.0, 47.4) 62.4 (19.4, 94.8) 9.0 (9.0, 22.0) 18.14 (9.0, 41.2)
IL-2 3.0 (3.0, 6.7) 3.0 (3.0, 11.0) 3.0 (3.0, 3.8) 3.0 (3.0, 14.3) 3.0 (3.0, 3.0) 3.0 (3.0, 3.0)
IL-2R 106 (12, 297) 132 (12, 860) 164 (91.3, 577) 113 (26.0, 1036) 40.2 (12.0, 139) 60.3 (12.0, 540)
IL-4 2.5 (2.5, 2.5) 4.6 (2.5, 22.2) 2.5 (2.5, 27.7) 2.5 (2.5, 27.7) 2.5 (2.5, 2.5) 2.5 (2.5, 8.6)
IL-5 4.7 (1.5, 12.1) 6.5 (1.5, 27.4) 3.5 (2.7, 8.5) 3.8 (3.5, 26.3) 3.1 (1.5, 4.4) 3.8 (1.5, 10.7)
IL-6 34.41 (11.1, 83.5) 24.22 (15.7, 99.5) 34.9 (13.0, 152) 16.0 (4.3, 63.1) 8.1 (4.0, 11.3) 7.3 (2.2, 22.8)
IL-7 28.51 (13.8, 72.2) 22.6 (7.7, 69.9) 36.2 (12.1, 60.9) 29.3 (5.0, 69.3) 16.3 (5.0, 21.7) 12.6 (3.3, 39.2)
IL-10 2.5 (2.5, 9.8) 5.6 (2.5, 12.7) 2.5 (2.5, 6.7) 2.5 (2.5, 13.9) 2.5 (2.5, 2.5) 2.5 (2.5, 7.1)
IL-12 30.61 (12.6, 49.6) 41.5 (19.1, 123) 23.6 (10.9, 59.8) 33.3 (17.4, 124) 15.5 (7.7, 23.1) 18.4 (7.2, 55.6)
IL-13 29.4 (20.5, 48.0) 45.5 (20.2, 102) 29.9 (22.5, 59.0) 35.3 (25.3, 115) 24.4 (20.5, 30.0) 25.8 (21.0, 69.0)
IL-15 11.0 (5.0, 50.9) 16.5 (5.0, 115) 12.5 (5.0, 81.7) 19.0 (5.0, 157) 5.0 (5.0, 5.0) 5.0 (5.0, 71.1)
IL-17 44.9 (8.0, 163) 1163 (8.0, 314) 36.3 (8.0, 171) 86.3 (8.0, 354) 8.0 (8.0, 22.3) 18.2 (8.0, 202)
GM-CSF 21.5 (7.5, 76.4) 56.43 (9.3, 151) 20.1 (5.5, 103) 38.6 (22.4, 209) 17.0 (6.6, 28.9) 31.7 (7.5, 105)
IFN-a 24.5 (20.8, 55.5) 58.53 (20.8, 141) 24.5 (19.8, 87.9) 48.1 (27.9, 143) 20.8 (15.7, 32.6) 31.2 (17.8, 78.9)
IFN-c 2.5 (2.5, 13.7) 6.2 (2.5, 48.2) 2.5 (2.5, 26.4) 2.5 (2.5, 70.4) 2.5 (2.5, 2.5) 2.5 (2.5, 27.2)
TNF-a 2.5 (2.5, 8.9) 4.1 (2.5, 11.9) 2.5 (2.5, 7.0) 11.8 (2.5, 15.7) 2.5 (2.5, 2.5) 2.5 (2.5, 7.4)
CXCL8 1096 (375, 3357) 1389 (316, 3342) 1715 (460, 6500) 681 (340, 3095) 650 (322, 1226) 400 (192, 1416)
CXCL9 128 (44.3, 242) 73.6 (12.0, 237) 191 (89, 268) 157 (43, 248) 91.7 (42.7, 154) 60.1 (18.4, 176)
CXCL10 52.6 (31.6, 105) 15.2 (7.1, 32.0) 193 (51.5, 328) 16.4 (9.5, 32.3) 59.8 (25.7, 95.0) 16.3 (5.9, 64.6)
CCL2 298 (159, 413) 345 (180, 502) 317 (188, 589) 269 (148, 393) 193 (128, 229) 184 (111, 349)
CCL3 26.9 (16.1, 71.7) 41.9 (16.9, 107) 45.4 (27.3, 92.0) 82.6 (20.7, 163) 20.8 (17.4, 30.6) 26.1 (17.4, 59.4)
CCL4 30.1 (19.0, 92.8) 47.1 (19.9, 124) 128 (40.3, 372) 59.1 (30.8, 145) 27.8 (17.1, 40.9) 36.54 (14.6, 97.0)
CCL5 42.8 (32.0, 66.3) 29.3 (19.4, 56.8) 58.4 (35.0, 110) 31.1 (18.5, 66.4) 37.3 (22.4, 45.8) 32.5 (7.5, 48.9)
CCL11 2.5 (2.5, 7.8) 2.5 (2.5, 12.0) 3.8 (2.5, 6.0) 2.5 (2.5, 6.2) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5)
Data presented as median (IQR). All results pg/ml.
Results with superscript numerals had significance tests ,0.05. Specifically,
1pre-dexamethasone smokers vs. never-smokers with asthma,
2post-dexamethasone smokers vs. never smokers with asthma,
3pre-dexamethasone vs. post-dexamethasone smokers with asthma,
4pre-dexamethasone vs. post-dexamethasone never smokers with asthma.
Cytokine abbreviations: CXC; CXC chemokine motif ligand, CCL; CC chemokine motif ligand, GM-CSF; granulocyte macrophage colony-stimulating factor, IFN; interferon
IL; interleukin, TNF; tumor necrosis factor.
doi:10.1371/journal.pone.0071460.t003
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example, airway epithelial appearances in asthma are known to be
altered by current smoking [18,26] and current smokers with
asthma show attenuated responses to both inhaled and oral
corticosteroids [1,2,3,4,5,6,7,8,9]. However little is known about
the mechanisms by which current cigarette smoking drives this
altered phenotype. Whilst asthma is typically described as a
prototypical Th2 disease, it has more recently been suggested to be
more accurate to view asthma as a heterogeneous condition given
the disappointing responses observed to immuno-therapies target-
ed against key Th2 cytokines [27,28]. Current smokers with
asthma are common in clinical practice and can be argued to
represent a further ‘subtype’ given their clinical behavior and
altered airway cytokine profiles compared to never smokers with
asthma.
We present evidence that current smokers with asthma have
increased sputum supernatant concentrations of IL6, 7 and 12 and
an absence of sputum neutrophilia. The lack of improvement in
lung function to oral dexamethasone in this cohort also suggests
the presence of corticosteroid resistant airways disease. We used
oral dexamethasone as it allowed detection of suppression of
serum cortisol as an indicator of compliance with the corticoste-
roid trial. Therefore we are confident that we are not observing a
reduced lung function response due to poor adherence.
Our results demonstrate that IL6 is elevated in both current
and ex-smokers with asthma and this cytokine also failed to
respond to oral dexamethasone. Of interest is our previous
observation that treatment with low dose theophylline is
associated with a fall in sputum supernatant IL-6 concentration
in current smokers with asthma (unpublished observations and
[24]). IL-6 is a pleiotropic cytokine which has an important role
in Th-17 cell development and is elevated in viral exacerbations
of airways disease; a state recognized to be relatively cortico-
steroid resistant [29,30]. Bronchoalveolar lavage samples from
corticosteroid resistant non-smokers with asthma have also
demonstrated increased concentrations of IL-6 [31] and
therefore IL-6 may be promoting corticosteroid resistant
inflammation via promotion of Th17 development and activa-
tion. A second alternative explanation is that our results reflect
unchallenged promotion of IL-6 production via b2 agonists due
to a loss of corticosteroid sensitivity in the IL-6 gene [30]. A
third potential explanation is the observed increased concentra-
tion of sputum supernatant IL-6 reflects increased local
production in an attempt to suppress inflammation [32,33].
Whilst our study only includes a small number of ex-smokers
with asthma, we provide some evidence that ex-smokers with
asthma have ongoing inflammatory signaling despite smoking
cessation and perhaps a differing sputum cytokine profile from
current smokers with asthma. The reasons why this pattern exists
in ex-smokers with asthma is not entirely clear but may reflect a
persistent permissive effect of smoking on cytokine expression at a
transcriptional level.
Few sputum supernatant cytokine concentrations were observed
to change significantly in response to oral dexamethasone.
Interestingly, IFNa and IL-17 increased after oral dexamethasone
in current smokers with asthma. Impaired IFNa production has
been linked to the development of viral-induced exacerbations of
asthma [34]. Little is known about the response of current smokers
with asthma to viral infections and their subsequent response to
corticosteroids. However our results suggest that a corticosteroid
sensitive and potentially appropriate response is present in this
group. In contrast the observed increase in IL-17 suggests a
potential mechanism for the poor lung function response to
corticosteroids of smokers with asthma. The observed dexameth-
asone related increase in sputum supernatant IL-17 is of interest
given the known links between IL-17 and corticosteroid insensitive
inflammation and suggests a potential role for IL-17 and perhaps
Th17 cells in the altered corticosteroid responses of smokers with
asthma [35].
Current smokers with asthma had significantly lower concen-
trations of plasma IL-1RA, 12, 13 and GM-CSF compared to non
smokers with asthma. This reduction in plasma cytokines in
contrast to elevation of a number of airway cytokines suggests that
Table 4. Principal component analysis of pre dexamethasone sputum supernatant cytokines.
PC1 PC2 PC3
(57% total variance) (21% total variance) (15% total variance)
IL-1RA 0.105 0.169 20.184
IL-2R 0.326 20.063 0.080
IL-6 0.082 0.456 20.012
IL-7 0.322 0.013 0.100
IL-12 0.326 20.104 20.003
IL-13 0.312 20.164 0.033
IL-17 0.316 20.154 0.015
GM-CSF 0.310 20.178 0.054
IFN-a 0.321 20.130 0.054
CXCL8 0.010 0.151 20.588
CXCL9 0.155 0.408 0.199
CXCL10 0.074 0.436 0.228
CCL2 0.131 0.394 20.046
CCL3 0.246 0.033 20.372
CCL4 0.106 0.137 20.549
CCL5 0.224 0.278 0.241
doi:10.1371/journal.pone.0071460.t004
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current smokers with asthma, in contrast to COPD, do not suffer
from a generalized systemic inflammation due to an ‘overspill’ of
pulmonary inflammation. The disparity between the sputum and
systemic cytokine concentrations also lead us to suggest that future
studies should aim to measure cytokines from airway samples in
addition to peripheral blood in asthma as valuable insights may
otherwise be missed.
Whilst this is the first study providing an assessment of a wide
range of airway cytokines in smokers and ex-smokers with asthma,
we recruited a relatively small number of participants, particularly
ex-smokers with asthma, and our results require corroboration in
further studies. Finally we did not examine the cellular source of
the cytokines measured in this study therefore our conclusions
require validation using airway cell preparations isolated from
BAL or sputum and bronchial brushings.
Conclusions
Current smokers with asthma display alterations of both
sputum supernatant and peripheral cytokine profiles when
compared to never smokers with asthma. Elevated sputum
cytokines in current smokers with asthma are unresponsive to
oral corticosteroids and are associated with a poor lung function
response. Ex-smokers with asthma may display a differing
airway cytokine profile to current smokers with asthma but
further work is required to examine this possibility. Given our
findings we suggest that ex-smokers with asthma could represent
a distinct group and caution against viewing ex-smokers with
asthma as automatically equivalent to current smokers with
asthma. Finally future studies should endeavor to determine the
airway cellular sources of the elevated cytokine concentrations
in current and ex-smokers with asthma and to evaluate how
cigarette smoking induced cytokine changes could be driving
relatively corticosteroid resistant airway inflammation as such
efforts will support development of novel targeted therapies for
asthma.
Table 5. Plasma cytokine concentrations before and after two weeks of oral dexamethasone.
Smokers with asthma Never smokers with asthma
Pre-steroid Post-steroid Pre-steroid Post-steroid
(n =19) (n=18) (n=20) (n =17)
IL-1RA 2091 (160, 252) 1422 (114, 185) 247 (220, 284) 1794 (160, 215)
IL-1b 9.0 (9.0, 20.1) 9.0 (9.0, 11.4) 9.0 (9.0, 17.3) 9.0 (9.0, 19.7)
IL-2 3.0 (3.0, 3.0) 3.0 (3.0, 3.0) 3.0 (3.0, 6.6) 3.0 (3.0, 8.0)
IL-2R 294 (165, 355) 1773 (128, 223) 251 (211, 306) 1954 (161, 233)
IL-4 9.7 (6.3, 11.3) 6.33 (2.5, 9.3) 10.5 (8.7, 12.7) 7.34 (5.3, 11.7)
IL-5 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5)
IL-6 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 3.3) 1.5 (1.5, 5.4)
IL-7 16.3 (5.0, 18.0) 5.0 2,3 (5.0, 14.7) 19.7 (14.7, 25.2) 15.4 (12.6, 20.5)
IL-10 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5)
IL-12 69.11 (46.0, 76.1) 58.1 3 (39.1, 65.8) 70.9 (63.6, 86.1) 53.24 (47.8, 59.9)
IL-13 19.51 (17.4, 21.5) 19.52 (17.2, 21.5) 21.5 (19.7, 23.4) 21.5 (19.5, 26.3)
IL-15 5.0 (5.0, 5.0) 5.0 (5.0, 5.0) 5.0 (5.0, 5.0) 5.0 (5.0, 11.9)
IL-17 22.6 (8.0, 47.7) 8.0 (8.0, 40.5) 33.4 (16.3, 56.2) 28.3 (8.0, 43.1)
GM-CSF 6.61 (5.1, 13.0) 10.3 (4.5, 12.1) 10.3 (10.3, 26.1) 10.3 (6.6, 25.2)
IFN-a 31.2 (24.5, 34.3) 29.52 (24.5, 34.3) 32.7 (28.3, 39.4) 34.3 (31.2, 40.2)
IFN-c 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5)
TNF-a 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5)
CXCL8 5.1 (3.6, 6.8) 4.33 (2.6, 5.0) 6.1 (2.4, 8.0) 4.04 (1.5, 6.2)
CXCL9 12.0 (12.0, 12.0) 12.0 (12.0, 12.0) 12.0 (12.0, 14.6) 12.0 (12.0, 12.0)
CXCL10 10.0 (8.1, 17.0) 2.52, 3 (2.5, 5.4) 14.5 (10.6, 18.5) 6.44 (2.5, 10.7)
CCL2 175 (116, 259) 1173 (86, 184) 165 (147, 238) 122 (98.5, 208)
CCL3 24.1 (19.1, 25.7) 20.82 (19.5, 22.4) 24.1 (24.1, 27.3) 24.1 (22.4, 27.3)
CCL4 27.8 (24.4, 31.3) 24.42,3 (21.4, 30.1) 31.3 (27.0, 35.6) 30.1 (27.2, 32.7)
CCL5 4639 (3653, 6269) 32733 (2852, 4230) 6387 (4245, 9545) 47734 (3383, 5537)
CCL11 88.8 (50.6, 130) 1493 (91.0, 210) 75.4 (42.3, 86.7) 1014 (81.4, 126)
Data presented as median (IQR). All results pg/ml.
Results with superscript numerals had significance tests ,0.05. Specifically,
1pre-dexamethasone smokers vs. never smokers with asthma,
2post-dexamethasone smokers vs. never smokers with asthma,
3pre- vs. post-dexamethasone smokers with asthma,
4pre- vs. post-dexamethasone never smokers with asthma.
doi:10.1371/journal.pone.0071460.t005
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Supporting Information
Figure S1 Principal component analysis plot of pre
dexamethasone sputum supernatant cytokines (IL1b,
1RA, 2R, 6, 7, 13, 17, IFNa, GMCSF, CCL2, 3, 4 & 5,
CXCL8, 9 & 10) including data from ex-smokers with
asthma. Principal component 1 represents 57% of variance in
data, Principal component 2 16%. Based on examination of the
component loadings we interpret principal component 1 as being
principally driven by the sputum supernatant cytokines IFNa,
IL1b, 2R, 7, 12, 13, 17 & GMCSF and principal component 2
IL6, 8, CCL2, 4 and CXCL10.
(TIF)
Table S1 Number and percentage of sputum superna-
tant samples per cytokine (grouped according to smok-
ing history) below the manufacturer’s recommended
lower limit of detection.
(DOCX)
Table S2 Comparison of smokers with never smokers
with asthma pre and post dexamethasone.
(DOCX)
Table S3 Number and percentage of serum samples per
cytokine (grouped according to smoking history) below
the manufacturer’s recommended lower limit of detec-
tion.
(DOCX)
Text S1 Few statistically significant within-group
changes were evident in the ex-smokers with asthma
group in response to oral dexamethasone. However ex-
smokers with asthma did demonstrated a reduction in CCL5
(221.7 pg/ml (241, 23), p = 0.03) and CXCL10 (2147.7 pg/ml
(2251, 245), p = 0.01).
(DOCX)
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